MARKET

AEZS

AEZS

Aeterna Zentaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6244
+0.0101
+1.64%
After Hours: 0.6300 +0.0056 +0.90% 19:10 09/17 EDT
OPEN
0.6000
PREV CLOSE
0.6143
HIGH
0.6260
LOW
0.5920
VOLUME
779.07K
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
0.2900
MARKET CAP
75.74M
P/E (TTM)
-8.5534
1D
5D
1M
3M
1Y
5Y
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...
GlobeNewswire · 09/08 12:00
BRIEF-Aeterna Zentaris Provides Pipeline Program Updates
reuters.com · 08/04 21:43
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong balance sheet with current cash of approximately $70 milli...
GlobeNewswire · 08/04 20:05
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic...
GlobeNewswire · 07/29 12:05
We Think Aeterna Zentaris (TSE:AEZS) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 06/28 05:56
Hedge Funds Are Buying AEterna Zentaris Inc. (AEZS)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in re...
Insider Monkey · 06/13 18:10
Mid-Day Market Update: United Natural Foods Falls On Sales Miss; Aethlon Medical Shares Jump
Midway through trading Wednesday, the Dow traded up 0.09% to 34,631.35 while the NASDAQ rose 0.29% to 13,964.96. The S&P also rose, gaining 0.15% to 4,233.76.
Benzinga · 06/09 16:24
Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis
Benzinga · 05/17 14:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEZS. Analyze the recent business situations of Aeterna Zentaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AEZS stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 2.21M
% Owned: 1.82%
Shares Outstanding: 121.30M
TypeInstitutionsShares
Increased
6
102.11K
New
8
645.49K
Decreased
9
621.32K
Sold Out
6
161.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Carolyn Egbert
President/Chief Executive Officer/Director
Klaus Paulini
Chief Financial Officer/Senior Vice President
Leslie Auld
Senior Vice President/Managing Director
Eckhard Gunther
Senior Vice President
Nicola Ammer
Vice President - Finance
Guenther Grau
Vice President
Matthias Gerlach
Director
Dennis Turpin
Independent Director
Pierre-Yves Desbiens
Independent Director
Peter Edwards
Independent Director
Gilles Gagnon
No Data
  • All
  • Financials
  • Insiders
More
About AEZS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company. The Company is focused on developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. Its business is to finalize the development, manufacturing, registration and commercialization of Macrilen (macimorelin). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and that has potential uses in both endocrinology and oncology indications. Macimorelin is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical and compelling safety profile of macimorelin in developing diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.